8:00 am Morning Check-In: Served with coffee + light breakfast
8:55 am Chair’s Opening Remarks
Aligning Science, Strategy & Stakeholders To Accelerate Commercial Translation In Dermatology Drug Development
9:00 am Panel Discussion: Bridging Science and Strategy: Funding the Next Wave of Dermatology Innovation
Synopsis
- Trends in capital allocation across indications, modalities, and stages of development in dermatology
- Key factors that shape investor and pharma conviction in early-stage assets and platforms
- How clinical trial design, endpoints, and market access considerations influence fundability
- Strategies for building successful partnerships and aligning with pharma and investor expectations
9:30 am Roundtable Discussion: Pathways to Reimbursement Success in Immuno-Dermatology: Insights from the Reimbursor Perspective
Synopsis
- Explore key metrics and data requirements reimbursement bodies prioritize to ensure therapies are deemed clinically and economically viable
- Learn how data informs reimbursement decisions and substantiates long-term value propositions for immuno-dermatology therapies
- Gain insights into harmonizing trial design and endpoints with HTA criteria to address unmet needs
10:30 am Morning Break & Refreshments
Innovative Pathways & Novel Modalities Driving The Next Wave Of Inflammatory Skin Disease Therapeutics
11:00 am TIRmed’s TIR‑C: Advancing Topical Oligonucleotide Therapy for Atopic Dermatitis into the Clinic
Synopsis
- TIR‑C aims to relieve itch and regenerate tissue without systemic side effects, thereby directly modulating skin immune cells (e.g., dendritic, mast cells, IL‑10 induction)
- Outlining nonclinical toxicology and regulatory approaches for CTA approval ahead of planned Phase I trial in 2026
- After Phase I safety and tolerability results TIRmed will prepare for Phase Ib targeting efficacy in mild-to-moderate AD positioning the program as a second line treatment after corticosteroids
11:30 am SFA-002: A Novel Oral Drug for Treating Autoimmune Disease: Results in Psoriasis
Synopsis
- Outlining SFA-002 mechanism of action by immunomodulation over immunosuppression
- Preclinical, phase Ia and phase Ib efficacy findings
- Safety profile
- Durable responses
- Special populations – scalp/palmoplantar psoriasis cohorts
- Differentiation strategy: convenience, cost, and multi-pathway modulation
12:00 pm Lunch & Networking
Innovating For Rare Dermatology: Navigating Funding, Regulatory Pathways, And Adaptive Trial Strategies
1:00 pm Rethinking Rare Dermatology: Advancing Topical & Systemic Innovation in Gorlin Syndrome and Dystrophic EB
Synopsis
- Comparing topical and systemic strategies for treating rare dermatologic diseases
- Highlighting unmet systemic needs and treatment limitations in dystrophic EB
- Showcasing progress in managing basal cell carcinoma burden in Gorlin syndrome
- Sharing expanded data and previewing pipeline growth and potential acquisition news
1:30 pm Advancing Topical Therapies for Rare Dermatologic Diseases for Safer, More Targeted Treatment
Synopsis
- Enabling topical delivery of novel molecules, aiming to reduce systemic exposure and adverse events in rare skin conditions
- Understanding the different regulatory and funding approaches required for the rare space
- SGT-610, currently in Phase 3 for Gorlin Syndrome, offers an alternative to systemic hedgehog inhibitors with a potentially improved safety profile
- SGT-210, in Phase 1 for Darier disease and other rare disorders, represents a new approach to targeting keratin mutations through localized therapy
2:00 pm Afternoon Break & Refreshments
Redefining Dermatology For The Next Decade Through Innovation, Inclusion, & Patient-Centered Impact
2:30 pm Panel Discussion: Bridging the Innovation-Impact Gap: What Will Define the Next Decade of Dermatology Drug Development?
Synopsis
• How will new modalities (gene therapy, senotherapeutics, trispecifics) reshape
pipelines?
• What breakthroughs are needed to close the 80% treatment gap?
• How can we institutionalize patient-centric, implementation-first drug design?
• What changes are coming from FDA and EMA regarding animal testing, inclusion
criteria, and biomarkers?
• Who's responsible for driving system-wide adoption: industry, academia, or policy?
3:00 pm Transforming Skin Therapeutics through Next Generation Delivery Platforms
Synopsis
- Advancing transdermal penetration using ionic liquids to enable delivery of peptides and nucleic acids
- Sampling of dermal biomarkers for quantitative diagnosis of dermatological diseases
- Integrating nanoparticle and material platforms for precision topical delivery for treating dermatological disorders
3:30 pm Panel Discussion: Closing the Gap Between Innovation and Impact: Patient & Advocacy Perspectives in Modern Dermatology Drug Development
Synopsis
- What makes a trial truly worth participating in from a patient’s and dermatologist’s perspective? What are the key considerations – pros and cons?
- How can developers better reflect patient-perceived benefit, to ensure quality of life and daily function are both addressed as a holistic measure of disease improvement?
- Highlighting the importance of early and meaningful patient involvement in shaping trial goals, eligibility criteria and logistics to ensure trials reflect patient priorities
- Where do patients feel most underserved in dermatology today? What are the advocacy community’s top priorities for addressing gaps in care, support, and treatment innovation for stigmatized or neglected conditions?
- What limits the real-world impact of recent dermatology advances? How can industry meaningfully partner with advocacy groups to improve reach, education, and equitable access to treatment through Early Access Programs (EAPs) & Open Label Extensions (OLEs)?